Legal & General Group PLC Aprea Therapeutics, Inc. Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 12, 2021	SELL	$4.05 - $5.5 $5,155 - $7,001	-1,273 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$4.92 - $30.67 $167 - $1,042	-34 Reduced 2.6%	1,273 $6,000
Q3 2020 Nov 13, 2020	SELL	$21.66 - $38.86 $6,606 - $11,852	-305 Reduced 18.92%	1,307 $32,000
Q2 2020 Aug 14, 2020	BUY	$25.47 - $39.69 $14,416 - $22,464	566 Added 54.11%	1,612 $63,000
Q1 2020 May 14, 2020	SELL	$31.65 - $45.3 $7,437 - $10,645	-235 Reduced 18.35%	1,046 $36,000
Q4 2019 Feb 13, 2020	BUY	$18.94 - $49.53 $24,262 - $63,447	1,281 New	1,281 $59,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$3,488
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.